Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide

  • Palomo, Marta|||0000-0002-3261-6577
  • Vera, Manuel|||0000-0001-9937-7235
  • Martín, Susana
  • Torramadé-Moix, S.
  • Martínez Sánchez, Julia
  • Belen Moreno, A.
  • Carreras, Enric|||0000-0002-3134-9964
  • Escolar, Ginès
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Endothelial dysfunction is an earlier contributor to the development of atherosclerosis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful in this scenario. We evaluated changes induced by CKD on endothelial cell proteome and explored the effect of DF and the mechanisms involved. Human umbilical cord vein endothelial cells were exposed to sera from healthy donors (n = 20) and patients with end-stage renal disease on haemodialysis (n = 20). Differential protein expression was investigated by using a proteomic approach, Western blot and immunofluorescence. HDAC1 and HDAC2 overexpression was detected. Increased HDAC1 expression occurred at both cytoplasm and nucleus. These effects were dose-dependently inhibited by DF. Both the HDACs inhibitor trichostatin A and DF prevented the up-regulation of the endothelial dysfunction markers induced by the uraemic milieu: intercellular adhesion molecule-1, surface Toll-like receptor-4, von Willebrand Factor and reactive oxygen species. Moreover, DF down-regulated HDACs expression through the PI3/AKT signalling pathway. HDACs appear as key modulators of the CKD-induced endothelial dysfunction as specific blockade by trichostatin A or by DF prevents endothelial dysfunction responses to the CKD insult. Moreover, DF exerts its endothelial protective effect by inhibiting HDAC up-regulation likely through PI3K/AKT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide

  • Martínez Sánchez, Julia
  • Hamelmann, H.
  • Palomo, Marta|||0000-0002-3261-6577
  • Mir, Enrique
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Torramade, S.
  • Rovira, M.
  • Escolar, Ginès
  • Cordes, Steffen
  • Kalupa, Martina
  • Mertlitz, S.
  • Riesner, K.
  • Carreras, Enric|||0000-0002-3134-9964
  • Penack, Olaf|||0000-0003-4876-802X
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Angiogenesis and endothelial activation and dysfunction have been associated with acute graft-vs.-host disease (aGVHD), pointing to the endothelium as a potential target for pharmacological intervention. Defibrotide (DF) is a drug with an endothelium-protective effect that has been approved for the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Clinical data suggest that DF also reduces the incidence of aGVHD; however, the mechanisms of DF-mediated aGVHD regulation have not been examined. To investigate possible DF-mediated prophylactic and therapeutic mechanisms in aGVHD, we performed in vitro studies using endothelial cell (EC) lines. We found that DF significantly and dose-dependently suppressed EC proliferation and notably reduced their ability to form vascular tubes in Matrigel. To explore whether DF administered prophylactically or therapeutically has a significant effect on aGVHD endothelial dysfunction, ECs were exposed to media containing sera from patients with aGVHD (n = 22) in the absence or presence of DF and from patients that did not develop aGVHD (n = 13). ECs upregulated adhesion molecules (vascular cell adhesion molecule 1, intercellular adhesion molecule 1), the adherence junction protein VE-cadherin, von Willebrand factor (VWF), and Akt phosphorylation in response to aGVHD sera. These responses were suppressed upon treatment with DF. In summary, DF inhibits vascular angiogenesis and endothelial activation induced by sera from aGVHD patients. Our results support the view that DF has notable positive effects on endothelial biology during aGVHD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid, experimental studies in thromboelastometry

  • Koller, Tobias|||0000-0002-6247-0193
  • Kinast, Nadia
  • Guilarte Castellanos, Andres
  • Pérez García, Sergio|||0000-0003-4242-0858
  • Paniagua, Pilar|||0000-0002-0215-1561
  • Vintro, Xavi León|||0000-0002-9673-5786
  • Arranz, Jose Mateo
  • Vilalta, Noelia|||0000-0002-3961-3563
  • García, Ma. Victòria Moral
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Aznar-Salatti, Jose
  • Albaladejo, Gines Escolar
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Colloid fluids supplemented with adequate combinations of coagulation factor concentrates with the capability to restore coagulation could be a desirable future treatment component in massive transfusion. Starting from a coagulation factor and blood cell-free albumin solution we added Prothrombin Complex Concentrate, Fibrinogen Concentrate and Factor XIII in different combinations and concentrations to analyze their properties to restore thromboelastometry parameters without the use of plasma. Further analysis under the presence of platelets was performed for comparability to whole blood conditions. Albumin solutions enriched with Fibrinogen Concentrate, Factor XIII and Prothrombin Complex Concentrate at optimized concentrations show restoring coagulation potential. Prothrombin Complex Concentrate showed sufficient thrombin formation for inducing fibrinogen polymerization. The combination of Prothrombin Complex Concentrate and Fibrinogen Concentrate led to the formation of a stable in vitro fibrin clot. Fibrinogen and Factor XIII showed excellent capacity to improve fibrin clot firmness expressed as Amplitude at 10 min and Maximal Clot Firmness. Fibrinogen alone, or in combination with Factor XIII, was able to restore normal Amplitude at 10 min and Maximal Clot Firmness values. In the presence of platelets, the thromboelastometry surrogate parameter for thrombin generation (Clotting Time) improves and normalizes when compared to whole blood. Combinations of coagulation factor concentrates suspended in albumin solutions can restore thromboelastometry parameters in the absence of plasma. This kind of artificial colloid fluids with coagulation-restoring characteristics might offer new treatment alternatives for massive transfusion. Study registered at the institutional ethic committee "Institut de Recerca, Hospital Santa Creu i Sant Pau, with protocol number IIBSP-CFC-2013-165.